Timby Chapter 18: Intro to Cancer & Dudek Chapter 24: Cancer Nutrition
Pathophysiology, Classifications, and Etiology of Cancer
Fundamental Definition of Cancer
Characterized by abnormal, unrelated cell proliferation.
Cancerous neoplasms invade healthy tissue structures and compete directly with normal host cells for oxygen, nutrients, and physical space.
Neoplasm refers specifically to new, abnormal tissue growth without physiological purpose.
Malignant transformation alters cell surface structures, leading to variations in the cell membrane and the expression of tumor-specific antigens.
Classification by Tissue Origin
Carcinomas: Malignancies originating from epithelial tissue surfaces (e.g., skin, linings of body cavities, and visceral organ linings).
Adenocarcinomas: Malignancies originating specifically from glandular organ tissues.
Sarcomas: Malignancies arising from mesenchymal connective tissues, including bone, muscle, cartilage, and soft tissues.
Leukemias: Neoplasms of blood-forming elements originating within the bone marrow.
Lymphomas: Neoplastic proliferations originating from lymphoid tissue (e.g., lymph nodes, spleen, gastrointestinal lymphoid deposits, and testicles).
Myelomas: Malignant proliferations of antibody-producing plasma cells.
Mixed Types: Neoplasms that derive from multiple distinct embryonic germ layers or cellular lineages.
Comparison of Benign vs. Malignant Tumors
Benign Tumors:
Noncancerous and noninvasive to adjoining tissues.
Demonstrate a slow rate of cellular proliferation.
Encapsulated, well-differentiated, and do not metastasize.
Do not typically cause death unless expanding within a closed anatomical compartment that compresses vital structures (e.g., intracranial lesions).
Can occasionally be left untreated or managed with conservative surveillance.
Malignant Tumors:
True cancers characterized by anaplasia and autonomous, uncontrolled growth.
Highly invasive, infiltrating surrounding parenchyma.
Demonstrate altered cell membranes, loss of contact inhibition, and expression of unique tumor-specific antigens.
Capable of local invasion, lymphovascular permeation, and distant metastasis.
Carcinogenesis and Cellular Transformation
Carcinogenesis defines the multistep process of malignant transformation:
Initiation: Genetic insult altering cell DNA structure via environmental carcinogens or inherited genetic mutations.
Promotion: Mutated pre-neoplastic cells undergo stimulated proliferation, creating an expanded population within the immediate tissue microenvironment.
Progression: Clonal evolution leading to marked cellular atypia, architectural invasion of adjacent stroma, neoangiogenesis, and distant metastasis.
Molecular and Genetic Etiology
Primary mechanism involves cumulative DNA damage altering critical regulatory genes:
Proto-oncogenes: Normal regulatory genes responsible for promoting physiological cell growth, division, and replication. Mutations convert them into oncogenes, which function inappropriately without physiological inhibitory feedback.
Tumor Suppressor Genes: Normal protective genes responsible for downregulating cell division, repairing mismatched DNA sequences, and initiating apoptosis. Inactivation or mutational loss of function permits unregulated proliferation of damaged cells.
Epidemiology and Contributing Risk Factors
Cancer Incidence and Mortality
Second leading cause of death in the United States.
Overall lifetime probability: men and women develop cancer.
Leading cause of cancer death across both sexes: lung cancer.
Most frequent sites by sex:
Men: Prostate cancer, lung cancer, and colorectal cancer.
Women: Breast cancer, lung cancer, and colorectal cancer.
Contributing Factors and Carcinogenic Exposures
Chemical Carcinogens: Tobacco combustion products, nicotine, inhaled asbestos fibers, synthetic pesticides, and industrial formaldehydes.
Environmental Carcinogens: Prolonged solar ultraviolet (UV) radiation, ionizing radiation, industrial atmospheric pollutants, electromagnetic radiation, and close proximity to nuclear facilities.
Dietary and Lifestyle Influences: Diets rich in saturated fats and chemical nitrates/nitrites, chronic alcohol abuse, and obesity (where excess adipose tissue drives persistent, systemic, pro-inflammatory signaling).
Microbial Pathogens (Viruses and Bacteria):
Human Papillomavirus (HPV) (associated with cervical, anogenital, and oropharyngeal cancers).
Helicobacter pylori (associated with gastric adenocarcinoma and MALT lymphoma).
Human Herpesvirus 8 (associated with Kaposi sarcoma).
Iatrogenic and Pharmacological Agents: Prolonged systemic immunosuppressive therapy, hormone replacement therapies (HRT), and past therapeutic exposure to antineoplastic agents.
Immune Dysfunction: Impaired immune surveillance wherein cytotoxic T-lymphocytes and natural killer (NK) cells fail to identify aberrant tumor antigens or fail to mount an effector response, allowing malignant clones to proliferate.
Cancer Screening Recommendations and Clinical Manifestations
Evidence-Based Screening Guidelines
Mammography: Annually for females aged \,years; transitioned to every \,years () for females aged \,years and older, with the option to continue annual screening.
Clinical Breast Examination: Every \,years ().
Colonoscopy: Every \,years () starting at age \,years for average-risk individuals.
Guaiac Fecal Occult Blood Testing (gFOBT): Performed annually.
Prostate-Specific Antigen (PSA) and Digital Rectal Exam: Shared decision-making between clinician and client, typically initiated between ages \,and \,years.
Cervical Cytology (Pap Smear): Every \,years () beginning at age \,years.
Low-Dose Chest Computed Tomography (LDCT): Annually for individuals aged \,years who have a history of heavy smoking and currently smoke or have quit within the preceding \,years.
Genetic Risk Assessment: Recommended for individuals with significant family histories suggesting hereditary breast, ovarian, or non-polyposis colorectal cancer syndromes.
General Warning Signs: The CAUTION UP Mnemonic
C: Changes in bowel or bladder habits
A: A sore that does not heal
U: Unusual bleeding or discharge
T: Thickening or lump in breast or elsewhere
I: Indigestion or difficulty swallowing
O: Obvious changes in warts or moles
N: Nagging cough or persistent hoarseness
U: Unexplained weight loss
P: Pernicious anemia
Associated Non-Specific Manifestations: Intractable headaches, severe chronic pain, persistent debilitating fatigue, unexplained low-grade pyrexia, and recurrent opportunistic infections.
Organ-Specific Signs and Symptoms
Bladder and Kidney: Gross or microscopic hematuria, dysuria, burning upon micturition, and urinary frequency.
Breast: Palpable discrete nodule or diffuse thickening, localized pruritus, unilateral erythema, and nipple excoriation or retraction unrelated to pregnancy, lactation, or menstruation.
Cervical and Uterine: Metrorrhagia (intermenstrual bleeding), atypical vaginal discharge, severe dysmenorrhea, and menorrhagia.
Colorectal: Hematochezia, melena, occult fecal blood, and persistent alterations in caliber or regularity of bowel movements.
Endometrial: Abnormal postmenopausal or abnormal intermenstrual uterine bleeding and atypical discharge.
Laryngeal: Intractable chronic cough and persistent progressive hoarseness.
Leukemias: Pallor, generalized asthenia, unexplained weight loss, recurrent refractory infections, spontaneous ecchymoses, petechiae, deep bone and joint ache, and epistaxis.
Lung: Refractory hacking cough, hemoptysis, sensation of intrathoracic weight/fullness, and pleuritic chest pain.
Lymphomas: Painless, enlarged, rubbery lymphadenopathy; generalized pruritus; drenching night sweats; pyrexia of unknown origin; and involuntary weight loss.
Oral Cavity and Pharynx: Chronic, non-healing ulcerations located on the mucosa, tongue, or pharyngeal walls.
Ovarian: Typically asymptomatic until advanced; late manifestations include vague abdominal bloating, pelvic fullness, and early satiety.
Prostate: Attenuated, hesitant, or interrupted urinary stream, accompanied by chronic dull pain distributed across the lumbosacral spine, pelvis, or proximal femora.
Stomach: Persistent dyspepsia, postprandial epigastric fullness or pain, progressive weight loss, and hematemesis.
Skin: Ulcerative cutaneous lesions that resist re-epithelialization, warty excrescences, changing pigmentary patterns, irregular borders, and rapid enlargement of pre-existing nevi.
Testicular: Discrete painless testicular nodule, diffuse testicular enlargement, scrotal induration, acute hydrocele accumulation, dull aching groin or lower abdominal discomfort, and paraneoplastic gynecomastia.
Diagnostic Procedures, Staging, and Tumor Grading
Diagnostic Modalities
Serum Tumor Markers: Biomolecules synthesized and released by neoplasms:
Prostate-Specific Antigen (PSA) for prostatic adenocarcinoma.
Cancer Antigen () for breast malignancy monitoring.
Carbohydrate Antigen () for pancreatic and hepatobiliary tumors.
Carcinoembryonic Antigen (CEA) for colorectal and gastrointestinal carcinomas.
Hematological and Biochemical Profiles: Complete blood count (CBC) to detect cytopenias; Comprehensive Metabolic Panel (CMP) to detect hepatic or renal dysfunction and hypercalcemia.
Diagnostic Imaging:
Plain radiography (X-rays) for gross skeletal or pulmonary assessment.
Computed Tomography (CT) scans providing cross-sectional evaluation of tumor dimensions, tissue density, and regional invasive margins.
Magnetic Resonance Imaging (MRI) yielding high-resolution soft tissue structural delineation.
Positron Emission Tomography (PET) scanning identifying areas of elevated fluorodeoxyglucose metabolism ("hot spots") reflecting accelerated cellular proliferation.
Ultrasonography differentiating solid tissue neoplasms from fluid-filled cystic lesions within the breast, pelvis, chest, and abdomen.
Fluoroscopy tracking functional movement of anatomical conduits (e.g., barium swallow examinations).
Endoscopy and Biopsy:
Direct visual examination via gastroscopy, bronchoscopy, or colonoscopy.
Definitive histological verification via excisional, incisional, core needle, or fine-needle aspiration (FNA) biopsy, evaluated with cytopathology.
Histological Grading Systems
Measures the degree of cellular differentiation relative to the normal tissue of origin:
Grade I (Well-Differentiated): Cells closely resemble normal morphology and organization; low proliferative index.
Grade II (Moderately Differentiated): Cells retain recognizable structural features of the source tissue but exhibit evident abnormalities.
Grade III (Poorly Differentiated): Cells exhibit marked architectural and nuclear atypia; minimal resemblance to tissue of origin.
Grade IV (Undifferentiated / Anaplastic): Cells show no structural or functional resemblance to the parent tissue, with erratic, aggressive behavior.
Clinical and Pathological Staging Frameworks
Stage 0: Carcinoma in situ; pre-invasive neoplastic cells confined within the basement membrane.
Stage I: Localized malignancy confined to the organ of origin.
Stage II: Locally invasive primary tumor with regional lymph node involvement.
Stage III: Extensive regional tumor growth with extensive regional lymph node metastasis.
Stage IV: Advanced disease characterized by distant hematogenous metastases.
American Joint Committee on Cancer (AJCC) TNM Staging System
Primary Tumor ():
: Tumor dimensions between .
: Tumor dimensions between .
: Tumor dimensions exceeding .
: Tumor has directly broken through the cutaneous surface or fixed to the chest wall.
Regional Lymph Nodes ():
: No palpable or histologically positive lymph nodes detected.
: Clinician detects mobile, swollen regional lymph nodes.
: Nodes feel firmly swollen, matted, and lumpy.
: Infiltration involves supraclavicular or infraclavicular lymph node chains.
Distant Metastasis ():
: Biopsy or imaging reveals no evidence of distant metastasis.
: Distant organs demonstrate confirmed metastatic foci or micrometastatic deposits.
Surgical Management and Procedural Oncology
Surgical Objectives and Categories
Diagnostic: Provides definitive tissue samples to establish histopathologic type and guide targeted therapy.
Local Excision: Resection of the tumor margin along with a conservative rim of healthy adjacent parenchyma.
Wide (Radical) Excision: En-bloc removal of the primary tumor, wide surrounding clear margins, and draining regional lymphatic basins.
Prophylactic (Preventative) Surgery: Removal of non-malignant tissues or organs at high risk for transformation due to familial predispositions or genetic mutations.
Palliative Surgery: Procedures to relieve pain, bypass obstructions, stop hemorrhage, or decompress organs without curative intent.
Reconstructive (Plastic) Surgery: Procedures to restore cosmetic appearance and anatomical function following radical ablative surgeries.
Specialized Surgical and Destructive Modalities
Mohs Micrographic Surgery: Systematic tangential excision of thin cutaneous layers followed by intraoperative frozen-section microscopic examination of of tissue margins until no cancer cells remain; preserves maximum healthy tissue.
Chemosurgery: Sequential application of chemical escharotics (such as zinc chloride paste) directly to cutaneous cancers prior to excision.
Cryosurgery: Direct application of sub-zero liquid nitrogen to freeze and destroy neoplastic cellular structures.
Electrosurgery: Delivery of high-frequency alternating electric current to vaporize, cut, and coagulate malignant cells.
Laser Surgery: Precise delivery of laser energy for photoablation and photocoagulation of microscopic lesions.
Radiation Therapy and Clinical Radiation Protection
Radiobiological Mechanisms and Delivery Forms
Uses high-energy ionizing photons (gamma rays or X-rays) to induce single- and double-strand DNA breaks, arresting cellular division and initiating apoptosis.
External Radiation Therapy (ERT / Teletherapy): Linear accelerators deliver ionizing beams from an external source directed precisely at mapped tumor contours and regional lymphatic zones.
Internal Radiation Therapy (Brachytherapy): Sealed radioactive sources (seeds, ribbons, or capsules) placed directly into or adjacent to neoplastic tissue.
Systemic Internal Radiation Therapy: Unsealed radionuclides (such as Iodine-131 ()) administered orally, intravenously, or instilled into body cavities, concentrating metabolically in target tissues.
Adverse Effects of Ionizing Radiation
Integumentary Reactions: Alopecia, progressive erythema, dry or moist desquamation, and chronic subcutaneous fibrosis.
Gastrointestinal and Mucosal Effects: Stomatitis, xerostomia (salivary gland hypofunction), oral and gastrointestinal mucositis, anorexia, and intractable nausea.
Visceral Complications: Radiation cystitis, radiation pneumonitis, and late esophageal strictures.
Systemic Complications: Severe systemic fatigue and development of secondary malignancies.
Ocular and Reproductive Complications: Accelerated cataract formation and permanent gonadal sterility.
Myelosuppression: Direct radiation of red bone marrow causing leukopenia (depressed white blood cells) and thrombocytopenia (depressed platelets).
Radiation Safety and ALARA Principles
Time: Minimize hands-on direct contact time; maintain care delivery efficiency in designated private inpatient rooms.
Distance: Maximize physical clearance from the radiation source; radiation exposure falls off according to the inverse-square law ().
Shielding: Wear lead-lined aprons, thyroid shields, and utilize structural mobile lead barriers during clinical interactions.
Contamination Control: In unsealed systemic therapy, isolate client body fluids, bed linens, and personal protective equipment (PPE) as biohazardous radioactive waste.
Systemic Chemotherapy and Antineoplastic Pharmacology
Mechanisms and Therapeutic Classes
Disrupt cellular division by modifying or inhibiting RNA and DNA synthesis and interfering with cell cycle phases.
Alkylating Agents: Cross-link DNA strands, preventing replication and transcription.
Nitrosoureas: Cross the blood-brain barrier; alkylate DNA and inhibit key enzymatic processes.
Topoisomerase I Inhibitors: Induce reversible single-strand breaks in DNA, leading to lethal double-strand breaks during replication.
Antimetabolites: Mimic essential metabolites, halting nucleotide synthesis during the S-phase of the cell cycle.
Routes of Administration
Intravenous (IV): Administered via peripheral venipuncture, peripherally inserted central catheters (PICC), or surgically implanted subcutaneous access ports (port-a-cath).
Enteral (Oral): Tablets or liquids requiring adherence to oral chemo handling protocols.
Parenteral Alternatives: Intramuscular (IM) and Subcutaneous (SQ) injections.
Regional Delivery: Intrathecal (instilled across the blood-brain barrier into cerebrospinal fluid), intraperitoneal (instilled into the peritoneal cavity), and topical applications.
Chemotherapeutic Toxicities and Nursing Interventions
Bone Marrow Suppression: Profound myelosuppression leading to anemia, neutropenia, and thrombocytopenia.
Gastrointestinal Effects: Severe nausea, vomiting, mucositis, stomatitis, and anorexia.
Integumentary and Neurological: Alopecia, generalized fatigue, and peripheral neuropathy.
Hyperuricemia and Renal Protection: Massive cell breakdown elevates serum uric acid, risking gout, arthralgia, and uric acid nephropathy:
Maintain systemic hydration between .
Monitor for joint pain, peripheral edema, and renal dysfunction.
Clinical Red Flags: Instruct patients to report temperature elevations (/), acute neurological changes/altered level of consciousness (LOC), paresthesias, marked weight loss, and indicators of hypovolemia.
Stem Cell Transplantation and Targeted Biotherapies
Peripheral Blood Stem Cell Transplantation (PBSCT)
Rescues and reconstitutes hematopoietic bone marrow destroyed by myeloablative chemotherapy or whole-body irradiation.
Autologous Transplant: Client's own hematopoetic stem cells (HSC) are collected, cryopreserved, and reinfused following high-dose conditioning therapy; zero risk of graft-versus-host disease (GVHD).
Allogeneic Transplant: Stem cells harvested from an HLA-matched related or unrelated human donor; risks GVHD, requiring prophylactic immunosuppressants. May be administered as a non-myeloablative "mini-transplant".
Syngeneic Transplant: Stem cells donated by a genetically identical twin; eliminates GVHD risk without requiring immunosuppressive therapy.
Targeted and Biological Therapies
Biologic Response Modifiers (BRMs): Agents that modulate the host's immune response to eliminate or control malignant cells.
Nonspecific Biologic Response Modifiers: Intravesical Bacillus Calmette-Guérin (BCG) for superficial bladder cancer, stimulating broad local immune activation.
Monoclonal Antibodies (MOABs): Engineered antibodies targeting specific tumor antigens, receptors, or checkpoints (identifiable by the suffix "-mab").
Cancer Vaccines: Therapeutic preparations designed to elicit an antigen-specific cytotoxic T-cell response against existing neoplasms.
Hyperthermia: Application of targeted local or regional thermal energy () to damage tumor vasculature and sensitize cancer cells to radiation and chemotherapy.
Photodynamic Therapy (PDT): Intravenous administration of a photosensitizing compound followed by directed illumination with a specific wavelength of light to generate cytotoxic reactive singlet oxygen, destroying tumors and microvasculature.
Gene Therapy: Insertion, alteration, or editing of genes within somatic cells to correct defective pathways or induce tumor cell death.
Aromatase Inhibitors: Ensymatically block the peripheral conversion of androgens to estrogens, starving hormone receptor-positive neoplasms.
Oncologic Emergencies
Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
Ectopic antidiuretic hormone (ADH) secretion causes continuous renal free water reabsorption.
Leads to hypervolemia, dilutional hyponatremia, and cerebral edema.
Managed with fluid restriction, hypertonic or isotonic sodium chloride infusions, and loop diuretics.
Hypercalcemia of Malignancy
Driven by osteolytic metastases or parathyroid hormone-related peptide (PTHrP) release.
Manifests with confusion, lethargy, muscle weakness, hyporeflexia, polyuria, cardiac dysrhythmias, and constipation.
Managed with aggressive intravenous hydration, loop diuretics, bisphosphonates, and oral/intravenous phosphate therapy.
Superior Vena Cava (SVC) Syndrome
Extrinsic venous compression or thrombosis of the superior vena cava, commonly secondary to primary lung carcinoma or breast metastases.
Causes impaired venous drainage from the head, neck, and upper extremities, manifesting as facial edema, periorbital swelling, distended jugular veins, and dyspnea.
Requires emergency palliative external beam radiation therapy, steroids, or intravascular stenting.
Sepsis and Septic Shock
Severe neutropenia impairs host defenses, allowing minor infections to rapidly cause systemic bacteremia and shock.
Requires immediate blood cultures followed by the administration of intravenous broad-spectrum antibiotics within \,hour.
Spinal Cord Compression (SCC)
Direct epidural invasion or pathological vertebral collapse compressing the spinal thecal sac.
Manifests with progressive localized back pain, lower extremity motor weakness, paresthesias, and bowel/bladder dysfunction.
Managed emergently with high-dose intravenous corticosteroids, palliative radiation, or surgical spinal decompression.
Tumor Lysis Syndrome (TLS)
Rapid intracellular release of ions and metabolic byproducts following cytotoxic therapy for bulky tumors.
Marked by hyperkalemia, hyperphosphatemia, secondary hypocalcemia, and hyperuricemia.
Induces lethal cardiac dysrhythmias and acute uric acid nephropathy.
Managed with vigorous intravenous hydration, allopurinol or rasburicase, and emergent hemodialysis if refractory.
Cancer Nutrition, Cachexia, and Symptom-Directed Care
Nutritional Principles and Pathophysiology
Adiposity and high-calorie diets exacerbate chronic systemic inflammation, creating a pro-tumorigenic microenvironment.
Patients should maintain a nutrient-dense, plant-based diet while limiting nutrient-poor foods, red meats, refined sugars, and ethanol.
Cancer Cachexia: Involuntary, progressive wasting of skeletal muscle mass with or without adipose depletion, driven by catabolic cytokines; not fully reversible by standard caloric supplementation.
Therapy-Induced Nutritional Impairments
Surgical Sequelae:
Head/Neck: Loss of mastication, xerostomia, dysphagia, and loss of smell or taste.
Gastrointestinal Tract: Gastroparesis, early satiety, dumping syndrome, severe malabsorption, and dehydration.
Pancreas: Loss of exocrine enzymes and endocrine dysregulation causing brittle glycemic control.
Lung: Exertional dyspnea while eating, causing reduced oral intake.
Chemotherapy Sequelae: Marked anorexia, dynamic dysgeusia (taste alterations), stomatitis, early satiety, diarrhea, and constipation.
Radiation Sequelae:
Head and neck: Xerostomia, ageusia, and mucositis.
Chest/Thorax: Painful dysphagia, esophageal strictures, and pulmonary fibrosis.
Abdomen/Pelvis: Radiation enteritis, malabsorption, and mechanical bowel obstructions.
Central Nervous System: Central nausea, vomiting, anorexia, and lethargy.
Optimizing Oral Intake
Prioritize oral alimentation before using nasogastric (NG) tubes or percutaneous endoscopic gastrostomy (PEG) tubes.
Provide oral nutritional supplements providing between along with of protein per serving.
Consider appetite stimulants for select patients.
Daily multivitamin-mineral supplementation is recommended; discourage unverified fad diets.
Encourage daily low-impact exercise to preserve lean body mass and physical function.
Prevention of Foodborne Illness in Immunocompromised Clients
Refrigerate perishable items immediately following purchase.
Discard all stored leftovers after .
Thaw frozen goods in the refrigerator, never at room temperature.
Wash hands thoroughly before and after handling foodstuffs, eating, and using the bathroom.
Wash fresh produce thoroughly under running water.
Cook all meats to well-done temperatures; strictly avoid unpasteurized dairy, raw cheeses, and buffet-style dining.
Symptom-Specific Nutritional Management
Nausea: Rinse mouth before and after meals; eat small, frequent, low-fat, high-carbohydrate meals; hydrate with ginger tea, ginger ale, or electrolyte fluids.
Anorexia: Schedule small, calorie-dense, protein-rich snacks every ; consume foods chilled or at room temperature to minimize odor-induced aversions.
Fatigue: Engage in light exercise (e.g., short walks) early in the day to stimulate appetite.
Mouth Sores (Stomatitis): Maintain gentle oral hygiene using a soft-bristled toothbrush and saline rinses; avoid acidic, spicy, or rough foods; consume frozen fruit, popsicles, or ice cream for local cryoanalgesia.
Diarrhea: Ingest of fluid following each loose bowel movement; avoid caffeine, simple sugars, dairy, and high-fat foods.
Constipation: Increase insoluble dietary fiber; maintain fluid intake between ; encourage ambulation to stimulate peristalsis.
Palliative Care and Nursing Practice Standards
End-of-Life Nursing Care
Perform clinical procedures gently to avoid exacerbating pain.
Prioritize round-the-clock pain management.
Provide adequate hydration and nutrition tailored to patient comfort rather than strict caloric targets.
Maintain skin cleanliness, dryness, and protect vulnerable bony prominences.
Manage distressing environmental odors.
Protect client autonomy, cultural preferences, and personal dignity.
Core Nursing Diagnoses and Care Planning
Fatigue: Encourage high-protein, calorie-dense intake; coordinate nursing care around the client's peak energy periods.
Imbalanced Nutrition: Less Than Body Requirements: Plan meals to maximize caloric density; administer prescribed antiemetics prior to meals.
Disturbed Body Image: Explore individual emotional strengths, validate grief over changes in appearance (such as alopecia or surgical scarring), and offer referrals to supportive community resources.
Questions & Discussion
Practice Question 1
Question: A client has all of the following factors documented in his personal health history. Which would contribute most significantly to the development of oral cavity carcinoma?
A) Alcohol abuse
B) Poor dental hygiene
C) Frequent bouts of tonsillitis
D) Chewing smokeless tobacco
Answer: D) Chewing smokeless tobacco
Rationale: Although chronic alcohol use and poor oral hygiene increase risk, chewing smokeless tobacco delivers direct topical chemical carcinogens (such as nitrosamines) directly onto the oral mucosa, representing the single highest risk factor for oral malignancies.
Practice Question 2
Question: A nurse is conducting a skin assessment on a client. Which of the following characteristics of a mole on the skin warrants further evaluation by a physician?
A) Brown color
B) Irregular shape
C) Located on the neck
D) Skin around area sunburned
Answer: B) Irregular shape
Rationale: An irregularly shaped or asymmetrical mole warrants immediate referral, especially if the border is notched or if the lesion has altered its shape over time (reflecting the ABCDE criteria for melanoma).
Practice Question 3
Question: A client has frequent nausea and vomiting following radiation to the abdomen. The most appropriate intervention for the nurse to take is:
A) Administer antibiotics before meals.
B) Monitor fluid intake and output.
C) Serve the food while food is hot.
D) Provide music and conversation during meals.
Answer: B) Monitor fluid intake and output.
Rationale: Frequent vomiting following abdominal radiation places the client at high risk for dehydration and electrolyte disturbances; tracking intake and output is critical to guide fluid and electrolyte replacement. Hot foods exacerbate nausea via aromatic vapor emission, and antibiotics have no role in radiation-induced emesis.
Interactive Fill-In-The-Blank Challenge
Prompt: Both laryngeal and lung cancer can present with symptoms such as [_____1_____]. However, [_____2_____] cancer is more common. If it is caught quickly, however, the malignancy will not spread throughout the body and can be referred to as [_____3_____].
Selections:
1 - Swallowing difficulty, a cough, sore throat, or chest pain
2 - Laryngeal, or lung
3 - Stage 0, stage 1, benign, or undifferentiated
Correct Completed Statement: Both laryngeal and lung cancer can present with symptoms such as COUGH. However, LUNG cancer is more common. If it is caught quickly, however, the malignancy will not spread throughout the body and can be referred to as STAGE 1.
Surgical Management and Procedural Oncology
Surgical Objectives and Categories (Slide 26)
Diagnostic Confirmation: Biopsy provides pathology verification, establishes exact histology, and informs staging and targeted treatment planning.
Curative / Definitive Treatment: Resection aimed at complete excision of the malignant lesion.
Tumor Excision:
Local Excision: Resection of the tumor margin along with a conservative rim of healthy adjacent parenchyma.
Wide (Radical) Excision: En-bloc removal of the primary tumor, wide surrounding clear margins, and draining regional lymphatic basins.
Prophylactic (Preventative) Surgery: Removal of non-malignant tissues or organs at high risk for transformation due to strong family history or documented genetic predispositions (e.g., prophylactic mastectomy or oophorectomy).
Palliative Surgery: Procedures intended to relieve uncomfortable symptoms, decompress obstructed organs, bypass anatomical blocks, or control hemorrhage without curative intent.
Specialized Surgical and Destructive Modalities (Slide 27)
Reconstructive (Plastic) Surgery: Corrects physical and anatomical defects following radical ablative surgeries.
Mohs Micrographic Surgery: Systematic tangential shaving of thin cutaneous layers followed by intraoperative frozen-section microscopic examination of 100%100% of tissue margins until no cancer cells remain; spares maximal healthy tissue.
Chemosurgery: Sequential application of chemical escharotics (such as zinc chloride paste) directly to cutaneous cancers prior to excision.
Cryosurgery: Direct application of sub-zero liquid nitrogen to freeze and destroy neoplastic cellular structures.
Electrosurgery: Delivery of high-frequency alternating electric current to vaporize, cut, and coagulate malignant cells.
Laser Surgery: Precise delivery of laser energy for photoablation and photocoagulation of microscopic lesions.
Radiation Therapy and Clinical Radiation Protection
Radiobiological Mechanisms and Delivery Forms (Slide 28)
Uses high-energy "X-ray" ionizing photon beams that induce single- and double-strand DNA breaks, preventing cellular growth, division, and replication.
External Radiation Therapy (ERT / Teletherapy): High-energy ionizing beams delivered from a linear accelerator directed at mapped tumor contours and regional draining lymph nodes.
Internal Radiation Therapy (Brachytherapy): Sealed radioactive sources (seeds, ribbons, needles, or capsules) implanted directly into or adjacent to body cavities and tissues.
Systemic Internal Radiation Therapy: Unsealed radionuclides, such as Iodine-131 (131I131I), administered orally, intravenously, or instilled into body cavities, concentrating metabolically in target tissues.
Adverse Effects of Ionizing Radiation (Slide 29)
Acute Integumentary and Mucosal Effects: Alopecia, progressive erythema, dry or moist desquamation, stomatitis, oral mucositis, and xerostomia (salivary gland hypofunction).
Systemic and Visceral Toxicities: Systemic debilitating fatigue, anorexia, intractable nausea, radiation cystitis, and radiation pneumonitis.
Late and Long-Term Sequelae: Chronic subcutaneous tissue fibrosis, accelerated cataract formation, permanent sterility, and induction of secondary malignancies (new cancers).
Myelosuppression: Radiation exposure to red bone marrow causing severe hematologic suppression:
Leukopenia: Depressed white blood cell count predisposing to infection.
Thrombocytopenia: Depressed platelet count increasing bleeding risk.
Radiation Safety and ALARA Principles (Slide 30)
Time: Minimize hands-on direct contact time; deliver care efficiently in designated private inpatient rooms.
Distance: Maximize physical clearance from the radiation source; radiation intensity diminishes dramatically according to the inverse-square law (I∝1d2I∝d21).
Shielding: Wear lead-lined gowns/aprons, thyroid shields, and utilize structural mobile lead barriers during clinical interactions.
Contamination Management: Isolate radioactive body fluids, bed linens, and personal protective equipment (PPE), which represent the most commonly contaminated clinical articles.
Systemic Chemotherapy and Antineoplastic Pharmacology
Mechanisms and Therapeutic Classes (Slide 33)
Systemic antineoplastic agents interfere with cellular function by modifying or inhibiting RNA and DNA synthesis, halting uncontrolled cellular proliferation.
Alkylating Agents: Cross-link DNA strands, preventing replication and transcription.
Nitrosoureas: Cross the blood-brain barrier; alkylate DNA and inhibit key enzymatic processes.
Topoisomerase I Inhibitors: Induce reversible single-strand breaks in DNA, leading to lethal double-strand breaks during replication.
Antimetabolites: Mimic essential natural metabolites, halting nucleotide synthesis during the S-phase of the cell cycle.
Routes of Administration (Slide 33)
Intravenous (IV): Administered via peripheral venipuncture, peripherally inserted central catheters (PICC), or surgically implanted subcutaneous access ports (port-a-cath).
Oral (Enteral): Tablets or liquids requiring specialized handling protocols.
Parenteral Injections: Intramuscular (IM) and Subcutaneous (SQ) routes.
Regional / Cavitary Delivery: Intrathecal (instilled across the blood-brain barrier into cerebrospinal fluid), intraperitoneal (instilled directly into the peritoneal cavity), and topical applications.
Chemotherapeutic Toxicities and Nursing Interventions (Slide 34)
Systemic Adverse Effects: Profound myelosuppression, intractable nausea and vomiting, stomatitis, alopecia, and generalized fatigue.
Hyperuricemia and Renal Protection: Massive cellular destruction releases high purine loads, elevating serum uric acid and risking gout, joint pain, peripheral edema, and uric acid nephropathy:
Maintain aggressive systemic hydration between 2500 and 3000 mL/day2500 and 3000mL/day.
Monitor serum uric acid levels, joint pain, edema, and renal function markers.
Dietary Modifications: Provide small, frequent meals rather than large caloric loads.
Critical Clinical Red Flags to Report: Instruct clients to immediately report marked temperature elevations (≥38.0∘C≥38.0∘C / 100.4∘F100.4∘F), acute neurological changes or altered level of consciousness (LOC), peripheral neuropathy/paresthesias, rapid unexplained weight loss, and compromised hydration status.
Stem Cell Transplantation and Targeted Biotherapies
Peripheral Blood Stem Cell Transplantation (PBSCT) (Slide 35)
Replaces and reconstitutes hematopoietic bone marrow destroyed by high-dose myeloablative chemotherapy or whole-body irradiation to achieve cellular engraftment.
Autologous Transplant: Client's own stem cells are harvested, frozen (cryopreserved), and reinfused after high-dose therapy; zero risk of graft-versus-host disease (GVHD).
Allogeneic Transplant: Stem cells harvested from an HLA-matched human donor; carries significant GVHD risk requiring immunosuppressive therapy; can be administered as a non-myeloablative mini-transplant.
Syngeneic Transplant: Stem cells donated by a genetically identical twin with an identical tissue type; eliminates GVHD risk without requiring lifelong immunosuppressive drugs.
Targeted and Biological Therapies (Slide 36)
Biologic Response Modifiers (BRMs): Agents that alter the host's immunologic response to recognize and eradicate neoplastic cells.
Nonspecific Biologic Response Modifiers: Intravesical Bacillus Calmette-Guérin (BCG) instillations for superficial bladder cancer to stimulate local immune inflammation.
Monoclonal Antibodies (MOABs): Laboratory-engineered antibodies targeting specific cell-surface tumor antigens or immune checkpoints (identifiable by the suffix "-mab").
Cancer Vaccines: Therapeutic preparations designed to elicit an antigen-specific cytotoxic T-cell immune response.
Clinical Trials: Investigational protocols evaluating novel molecular targeted compounds.
Hyperthermia: Application of targeted thermal energy (41−43∘C41−43∘C) to damage tumor vasculature and sensitize cancer cells to antineoplastic therapy.
Photodynamic Therapy (PDT): Intravenous administration of a photosensitizing agent followed by targeted illumination with a specific laser wavelength, generating cytotoxic reactive singlet oxygen to ablate tumors.
Gene Therapy: Insertion or editing of genetic sequences within cells to correct molecular abnormalities or induce programmed apoptosis.
Aromatase Inhibitors: Enzymatically prevent the peripheral synthesis of estrogen, starving estrogen-dependent tumors (such as hormone receptor-positive breast cancers).
Oncologic Emergencies (Slide 37)
Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
Ectopic antidiuretic hormone (ADH) secretion causes continuous renal free water reabsorption.
Leads to hypervolemia, dilutional hyponatremia, and acute electrolyte imbalances.
Managed clinically with fluid restriction, sodium replacement, and loop diuretics.
Hypercalcemia of Malignancy
Driven by osteolytic bone destruction or secretion of parathyroid hormone-related peptide (PTHrP).
Manifests with lethargy, confusion, hyporeflexia, polyuria, cardiac dysrhythmias, and severe constipation.
Managed with aggressive intravenous fluid hydration, loop diuretics, and phosphate/bisphosphonate therapy.
Superior Vena Cava (SVC) Syndrome
Extrinsic compression or venous thrombosis of the SVC, commonly resulting from lung cancer invasion or metastatic breast cancer.
Obstructs venous return, causing congestion backed up into the head, neck, face, and upper extremities (manifesting as facial edema, periorbital swelling, and dyspnea).
Requires emergency palliative radiation therapy, intravascular stenting, and high-dose corticosteroids.
Sepsis and Septic Shock
Treatment-induced neutropenia severely compromises immune defense, predisposing patients to rapid bacterial dissemination.
Mandates STAT intravenous broad-spectrum antibiotic administration within 1 hour1hour following immediate blood cultures.
Spinal Cord Compression (SCC)
Direct tumor expansion or pathological vertebral bone collapse compressing the thecal sac and spinal cord.
Manifests with progressive localized back pain, lower extremity paresthesias, motor weakness, and bowel/bladder incontinence.
Managed emergently with high-dose intravenous steroids, radiation therapy, or surgical decompression.
Tumor Lysis Syndrome (TLS)
Massive, rapid lysis of neoplastic cells following cytotoxic therapy for bulky tumors.
Massive intracellular release overwhelms excretory pathways, producing hyperkalemia, hyperphosphatemia, secondary hypocalcemia, and hyperuricemia.
Induces lethal cardiac dysrhythmias and acute uric acid nephropathy.
Managed with vigorous intravenous hydration, allopurinol or rasburicase, and emergent hemodialysis if refractory.
Palliative Care and Nursing Practice Standards
Care of the Terminally Ill Client (Slide 38)
Carry out clinical tasks gently to avoid provoking pain or physical discomfort.
Prioritize aggressive, around-the-clock pain management.
Provide adequate fluid and nutritional support aligned with client comfort rather than caloric goals.
Keep the patient clean, warm, and dry, with meticulous attention to pressure points.
Manage distressing environmental odors.
Protect client autonomy, cultural preferences, and personal dignity.
Core Nursing Diagnoses and Care Planning (Slide 39)
Fatigue: Encourage high-protein and calorie-dense nutritional intake; schedule nursing care and physical activities around peak energy intervals.
Imbalanced Nutrition: Less Than Body Requirements: Plan meals to maximize caloric density; administer prescribed antiemetics prior to scheduled meals.
Disturbed Body Image: Explore individual strengths, validate emotional reactions to appearance changes (alopecia, scars), and connect clients to counseling and community resources.
Cancer Nutrition, Cachexia, and Symptom-Directed Care (Slides 40-47)
Nutritional Principles and Pathophysiology (Slide 41)
Maintain a healthy weight: excess adipose tissue fuels chronic systemic inflammation, creating a pro-tumorigenic microenvironment.
Emphasize a plant-based diet with variety (phytochemicals and cell-healing compounds remain actively studied).
Minimize consumption of nutrient-poor foods, red meats, refined sugars, and ethanol.
Cancer Cachexia: Involuntary, progressive wasting of skeletal muscle mass that cannot be fully reversed by conventional caloric nutritional support.
General nutritional complications are dictated by disease site (e.g., GI tumors producing abdominal discomfort/obstruction), cancer stage (suppressed appetite), and antineoplastic regimens (chemotherapy triggers profound nausea).
Therapy-Induced Nutritional Impairments
Surgical Complications (Slide 42):
Triggers increased metabolic demand for protein, total calories, Vitamin C, B-complex vitamins, and iron.
Head and Neck Surgery: Inability to chew, salivate, swallow, smell, taste, or see.
Gastrointestinal Tract Surgery: Early satiety, dumping syndrome, severe constipation, malabsorption, dehydration, and electrolyte disturbances.
Pancreatic Surgery: Exocrine deficiency and endocrine dysregulation causing brittle glycemic control.
Lung Surgery: Severe exertional dyspnea while eating, reducing oral intake.
Chemotherapy Complications (Slide 43):
Systemic effects: severe anorexia, nausea, vomiting, dynamic taste alterations (dysgeusia), sore mouth and throat, diarrhea, early satiety, and constipation.
Radiation Complications (Slide 44):
Head and Neck: Altered taste, severe dry mouth (xerostomia), dysphagia, loss of dentition, and painful mucositis.
Chest / Thorax: Dysphagia, esophageal stricture formation, nausea, vomiting, and fibrosis.
Abdomen / Pelvis: Intractable nausea, vomiting, diarrhea, malabsorption, and mechanical bowel obstructions.
Brain / CNS: Central anorexia, nausea, vomiting, and dysphagia.
Promoting Oral Intake (Slide 45)
Prioritize oral feeding before transitioning to nasogastric (NG) or percutaneous endoscopic gastrostomy (PEG) tubes.
Provide oral supplements supplying between 230 and 360 kcal230 and 360kcal and 10−20 g10−20g of protein per 8 oz8oz serving.
Consider appetite stimulants for select clients.
Daily multivitamin supplementation is safe and recommended; strictly avoid unverified fad diets (cancer patients should not be placed on restrictive diets).
Encourage regular physical movement as long as possible to support muscle mass and preserve functional status.
Foodborne Illness Prevention in Immunocompromised Clients (Slide 46)
Refrigerate all perishable foods immediately following purchase.
Discard all stored leftovers after 24 hours24hours.
Thaw frozen foods in the refrigerator, never at room temperature.
Practice strict hand hygiene before and after handling foodstuffs, eating, and using the bathroom.
Wash all fresh fruits and vegetables thoroughly under running water.
Cook all meats to well-done temperatures; strictly avoid raw cheeses, unpasteurized milk, and buffet-style dining.
Symptom-Specific Nutritional Management (Slide 47)
Nausea: Rinse mouth before and after eating; eat small, frequent meals; hydrate with electrolyte fluids, ginger ale, or ginger tea; consume high-carbohydrate, soft foods.
Anorexia: Plan menus in advance; consume calorie-dense, high-protein foods every 2 hours2hours; serve food cold or at room temperature to minimize offensive cooking odors.
Fatigue: Engage in low-impact physical exercise early in the day to stimulate appetite.
Mouth Sores (Stomatitis): Maintain oral hygiene with a soft-bristled toothbrush and saline rinses; avoid hard, rough, acidic, or spicy foods; consume frozen items (frozen fruit, ice cream, popsicles) for cryoanalgesic numbing.
Diarrhea: Drink 1 cup1cup of fluid after every loose bowel movement; limit caffeine, sugar-free products, dairy, and high-fat items.
Constipation: Increase dietary fiber intake; consume 8−10 cups/day8−10cups/day of fluids; engage in regular gentle walking to stimulate abdominal musculature and peristalsis.
Practice Questions and Discussion
Practice Question 1 (Slide 10)
Question: A client has all of the following factors documented in his personal health history. Which would contribute most significantly to the development of oral cavity carcinoma?
A) Alcohol abuse
B) Poor dental hygiene
C) Frequent bouts of tonsillitis
D) Chewing smokeless tobacco
Answer: D) Chewing smokeless tobacco
Rationale: Chewing smokeless tobacco exposes oral mucosa directly to concentrated chemical carcinogens (nitrosamines), posing the greatest single risk factor for oral malignancies.
Practice Question 2 (Slides 21-22)
Question: A nurse is conducting a skin assessment on a client. Which of the following characteristics of a mole on the skin warrants further evaluation by a physician?
A) Brown color
B) Irregular shape
C) Located on the neck
D) Skin around area sunburned
Answer: B) Irregular shape
Rationale: An irregularly shaped or asymmetrical mole warrants immediate evaluation, particularly if the lesion previously had a regular circular contour and has transformed over time.
Practice Question 3 (Slides 31-32)
Question: A client has frequent nausea and vomiting following radiation to the abdomen. The most appropriate intervention for the nurse to take is:
A) Administer antibiotics before meals.
B) Monitor fluid intake and output.
C) Serve the food while food is hot.
D) Provide music and conversation during meals.
Answer: B) Monitor fluid intake and output.
Rationale: Abdominal radiation causing frequent emesis creates severe dehydration and electrolyte imbalances. Closely monitoring intake and output is critical for managing fluid status. Hot foods release odors that exacerbate nausea, and antibiotics are not indicated.
Interactive Fill-In-The-Blank Challenge (Slides 24-25)
Prompt: Both laryngeal and lung cancer can present with symptoms such as [_____1_____]. However, [_____2_____] cancer is more common. If it is caught quickly, however, the malignancy will not spread throughout the body and can be referred to as [_____3_____].
Selections:
1 - Swallowing difficulty, a cough, sore throat, or chest pain
2 - Laryngeal, or lung
3 - Stage 0, stage 1, benign, or undifferentiated
Correct Completed Statement: Both laryngeal and lung cancer can present with symptoms such as COUGH. However, LUNG cancer is more common. If it is caught quickly, however, the malignancy will not spread throughout the body and can be referred to as STAGE 1.